Peptides derived from prodynorphin are decreased in basal ganglia of Huntington's disease brains.
The contents of methionine-enkephalin-Arg-Gly-Leu, dynorphin A, dynorphin B and alpha-neoendorphin have been measured in both control and Huntington's disease brains obtained postmortem. All 4 peptides were significantly reduced in the caudate nucleus and putamen of Huntington's disease compared with the control group. No differences were observed in frontal cortex or hypothalamus. Immunocytochemistry showed a marked depletion of dynorphin-like immunoreactivity in Huntington's disease substantia nigra.
Dawbarn
D
D
Zamir
N
N
Waters
C M
CM
Hunt
S P
SP
Emson
P C
PC
Brownstein
M J
MJ
D001479:Basal Ganglia / Q000032:analysis / Q000378:metabolism*; D002421:Caudate Nucleus / Q000032:analysis; D004399:Dynorphins / Q000031:analogs & derivatives / Q000032:analysis; D004723:Endorphins / Q000032:analysis; D004745:Enkephalins / Q000378:metabolism*; D005917:Globus Pallidus / Q000032:analysis; D006801:Humans; D006816:Huntington Disease / Q000378:metabolism*; D011498:Protein Precursors / Q000032:analysis / Q000378:metabolism*; D011699:Putamen / Q000032:analysis; D013378:Substantia Nigra / Q000378:metabolism
D004723:Endorphins; D004745:Enkephalins; D011498:Protein Precursors; C025681:alpha-neoendorphin; D004399:Dynorphins; C036200:rimorphin; C033660:preproenkephalin